144 related articles for article (PubMed ID: 36085013)
1. Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma.
Kim SI; Lee HC; Yoon HK; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Lee M
BMC Cancer; 2022 Sep; 22(1):965. PubMed ID: 36085013
[TBL] [Abstract][Full Text] [Related]
2. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma.
Kojima N; Yoshida H; Kuno I; Uehara T; Uno M; Ishikawa M; Kato T
Cancer Med; 2019 Aug; 8(10):4598-4604. PubMed ID: 31243928
[TBL] [Abstract][Full Text] [Related]
4. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
5. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
6. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
[TBL] [Abstract][Full Text] [Related]
8. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
9. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
10. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
11. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
[TBL] [Abstract][Full Text] [Related]
12. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Liang MI; Prendergast EN; Staples JN; Holschneider CH; Cohen JG; Cass I
J Surg Oncol; 2019 Sep; 120(4):779-785. PubMed ID: 31283034
[TBL] [Abstract][Full Text] [Related]
14. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088
[TBL] [Abstract][Full Text] [Related]
15. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
16. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
17. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
Lu H; Cunnea P; Nixon K; Rinne N; Aboagye EO; Fotopoulou C
Br J Cancer; 2021 Mar; 124(7):1286-1293. PubMed ID: 33473167
[TBL] [Abstract][Full Text] [Related]
19. Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma.
Kimyon Comert G; Turkmen O; Mesci CG; Karalok A; Sever O; Sinaci S; Boran N; Basaran D; Turan T
Tumori; 2019 Jun; 105(3):259-264. PubMed ID: 30915911
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]